Record quarterly revenue and strong automotive growth led to raised 2026 guidance for revenue, EBITDA, and free cash flow. A new $400M stock repurchase program was authorized, and the medical portfolio expanded via acquisition. Net leverage remains low and liquidity strong.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.